Medical Cannabis Advisory Group Urges Utah Legislature to Enhance Labeling of Semi-Synthetic THC Products

The Utah Medical Cannabis Advisory Group, convened by Utah Therapeutic Health Center’s Tim Pickett, is calling on the Utah Legislature to enact more stringent labeling requirements for THC products made via synthetic laboratory conversion of other cannabinoids.
“As a group of cannabis healthcare professionals, we ask that THC products available in Utah be requisitely and clearly labeled when they are made via a lab conversion from another cannabinoid, such as CBD. The process of these conversions may leave unidentifiable chemical byproducts that do not exist in nature and which pose health risks to patients. Therefore we propose imposing testing and labeling requirements so that this information may be made transparent to Utah patients. We believe these safety concerns, regarding both active semi-synthetic compounds and unknown chemical byproducts, warrant full disclosure to patients,” a November 8, 2021 letter from the Utah Medical Cannabis Advisory Group to the Utah Legislature says, in part. (The full text of the letter appears below.)
Four Pharmacy Medical Providers (PMPs) and two Qualified Medical Providers (QMPs) signed the letter.
Full Text of the November 8 Letter from The Utah Medical Cannabis Advisory Group:
Utah Medical Cannabis Advisory Group Statement on Labeling Semi-Synthetic THC Products
November 8, 2021
To the Utah State Legislature:
As a group of cannabis healthcare professionals, we ask that THC products available in Utah be requisitely and clearly labeled when they are made via a lab conversion from another cannabinoid, such as CBD. The process of these conversions may leave unidentifiable chemical byproducts that do not exist in nature and which pose health risks to patients. Therefore we propose imposing testing and labeling requirements so that this information may be made transparent to Utah patients. We believe these safety concerns, regarding both active semi-synthetic compounds and unknown chemical byproducts, warrant full disclosure to patients.
We stand with the Society of Cannabis Clinicians in accordance with their August 2021 statement,”SCC Consensus on Delta-8 THC.”
Signed,
The Utah Medical Cannabis Advisory Group
Cory Anden, MD
Kevin R. Baumgartner, PharmD
Josh Fitzgerald, PharmD
The Utah Cannabis Association Board
Mindy Madeo, RPh BSPharm
Tim Pickett, PA-C
Kylee Shumway, PharmD
The Utah Medical Cannabis Advisory Group works together to advocate for increased patient safety and access in the state’s Medical Cannabis program.
UT THC serves Medical Cannabis patients at its clinics in Salt Lake City, Ogden, Provo, Millcreek, Bountiful and Cedar City.
Media Contacts (Email contact is preferred.)
David Wells, Content Producer & Data Analystdave@utthc.com
(801) 336-8579

Courtney Lipscomb, Marketing Coordinatorcourtney@utthc.com
(801) 851-5554
About Utah Therapeutic Health CenterPioneers in the Utah Medical Cannabis space and big believers in the de-prescribe movement, Utah Therapeutic Health Center makes great efforts to innovate, educate, and destigmatize. Founded in 2020 by life-long Utahn and physician assistant Tim Pickett, UT THC actively works to educate patients, providers, and pharmacists alike.
Source: Utah Therapeutic Health Center